Our team
Our team, comprising clinicians, biologists, immunologists, biostatisticians, and technicians, focuses on both basic science with a translational angle and studying how to proactively screen for type 1 diabetes risk. With the patient’s goal of prevention and cure at the center, we aim to bridge clinical insights with laboratory research to advance innovative treatments and provide comprehensive care from early detection to treatment.


- Full Professor, Faculty of Medicine, KU Leuven
- Staff Endocrinologist of the Division Clinical Endocrinology, UZ Leuven
- Head of Leuven Diabetes Lab, KU Leuven
- President of the European Foundation for the Study of Diabetes (EFSD)
- Founder and President of INNODIA iVZW
- Founder of Hippo and Friends vzw


- Project Manager INNODIA (HARVEST)
- Project Manager pre-T1D Registry
- Project Manager EDENT1FI
Alumni


- PhD student Leuven Diabetes Lab, KU Leuven: 1,25-dihydroxyvitamin D3 and its analogues as immunomodulators in autoimmune type 1 diabetes: mechanisms of action and preclinical applications. 20 Apr 1998
- Current occupation: Staff Pediatrician, UZ Leuven (Belgium); Full Professor, Faculty of Medicine, KU Leuven, Belgium


- PhD student Leuven Diabetes Lab, KU Leuven: The study of immune-mediated destruction of islets of Langerhans in mouse models of type 1 diabetes. 23 May 2002
- Junior Postdoc Leuven Diabetes Lab, KU Leuven: June 2002-September 2006
- Senior Postdoc Leuven Diabetes Lab, KU Leuven: October 2006-September 2009
- Current occupation: Research Manager, Leuven Diabetes Lab, KU Leuven, Belgium


- PhD student Leuven Diabetes Lab, KU Leuven: Dysregulation of T lymphocyte apoptosis in the non-obese diabetic mouse, a model for type 1 diabetes. Sep 2003
- Current occupation: Staff Endocrinologist of the Division Clinical Endocrinology, UZ Leuven (Belgium); Full Professor, Faculty of Medicine, KU Leuven, Belgium


- PhD student Leuven Diabetes Lab, KU Leuven: Analogs of 1,25-dihydroxyvitamin D3 as immunomodulators: strategies to improve clinical applicability. 25 Nov 2004
- Junior Postdoc Leuven Diabetes Lab, KU Leuven: November 2004-July 2008
- Current occupation: Departmental Manager, CHROMETA KU Leuven, Belgium


- PhD student Leuven Diabetes Lab, KU Leuven: Beta-cell death in type 1 diabetes: How can we make stronger beta-cells? 24 Jun 2008
- Current occupation: CEO and co-founder AstriVax Therapeutics (Heverlee, Belgium)


- PhD student Leuven Diabetes Lab, KU Leuven: 1,25-Dihydroxyvitamin D3 and its analogues as modulators of dendritic cells. 31 May 2010
- Junior Postdoc Leuven Diabetes Lab, KU Leuven: October 2010-September 2013
- Senior Postdoc Leuven Diabetes Lab, KU Leuven: October 2013-June 2015
- Current occupation: Associate Director Global Regulatory Affairs, GSK (Waver, Rixensart, and Gembloux, Belgium)


- PhD student Leuven Diabetes Lab, KU Leuven: Molecular mechanisms of beta cell dysfunction and beta cell death in models of type 2 diabetes. 28 Oct 2010
- Junior Postdoc Leuven Diabetes Lab, KU Leuven: October 2014–July 2015
- Current occupation: COO & CFO, Associate Director Anti-Cancer Fund


- PhD student Leuven Diabetes Lab, KU Leuven: The role of diet in development and reversal of type 2 diabetes. 06 Jun 2015
- Current occupation: Staff Endocrinologist of the Division Clinical Endocrinology, UZ Leuven (Belgium); Part-time Assistant Professor, Faculty of Medicine, KU Leuven, Belgium


- Senior Postdoc Leuven Diabetes Lab, KU Leuven: April 2012–September 2015
- Current occupation: Project Manager, Clinical Trial Coordination, CellCarta (former HistoGeneX, Antwerp, Belgium)


- PhD student Leuven Diabetes Lab, KU Leuven: Interaction between the beta-cell and the immune system in type 1 diabetes: role for post-translational modifications. 21 Feb 2017
- Current occupation: Clinical Assessor Vaccines, Federal Agencyfor Medicines and Health Products (FAMHP, FAGG, and AFMPS) Belgium


- PhD student Leuven Diabetes Lab, KU Leuven: A novel Lactococcus lactis-based antigen-specific platform for the treatment of type 1 diabetes: Essential steps towards successful clinical translation. 06 Dec 2019
- Current occupation: Medical Affairs Manager Oncology, AstraZeneca (Dilbeek, Belgium)


- PhD student Leuven Diabetes Lab, KU Leuven: Neutrophils: a driving force in type 1 diabetes? 13 Nov 2023
- Current occupation: Investigation Expert, Legend Biotech (Antwerp, Belgium)


- PhD student Leuven Diabetes Lab, KU Leuven: Multi-omics technologies to identify biomarkers for therapy prediction and response in type 1 diabetes. 07 Nov 2023
- Current occupation: Biomarker Computational Scientist, Haya Therapeutics (Lausanne, Switzerland)